Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 527.8 crore (4.7% YoY growth) Gross Profit: Rs 186.5 crore (-1.3% YoY decline) Gross Margin: 35.0% (-190 bps YoY) EBITDA: Rs 67.5 crore (17.1% YoY growth) EBITDA Margin: 12.7% (+141 bps YoY) Profit After Tax (PAT): Rs 31.6 crore (12.2% YoY growth) PAT Margin: 5.9% (+43 bps YoY) Cash Profit After Tax: Rs 56.4 crore (14.6% YoY growth) FY25 Financial Highlights: Revenue from Operations: Rs 2,079.2 crore (compared to Rs 2,132.8 crore in FY24) Gross Profit: Rs 709.8 crore (compared to Rs 765.9 crore in FY24) Gross Margin: 33.8% (compared to 35.4% in FY24) EBITDA: Rs 224.6 crore (compared to Rs 261.6 crore in FY24) EBITDA Margin: 10.7% (compared to 12.1% in FY24) Profit After Tax (PAT): Rs 101.0 crore (compared to Rs 135.4 crore in FY24) PAT Margin: 4.8% (compared to 6.3% in FY24) Cash Profit After Tax: Rs 185.1 crore (compared to Rs 208.5 crore in FY24) Commenting on the performance, Vikas Gupta, Joint Managing Director said, “In Q4FY25, we delivered sustainable performance, with the Ibuprofen segment showing improved traction despite intense competition and continued pricing pressure in global markets. A key highlight was the successful commissioning of our fully backward-integrated Paracetamol production unit, with an installed capacity of 10,800 MTPA. This has tripled our Paracetamol capacity, enabling us to strengthen our non-Ibuprofen portfolio, particularly in high-demand, fast-moving therapeutic categories. Notably, pricing and demand across our broader API basket remained stable. However the chemicals segment delivered stable performance despite muted volumes, as enhanced operational efficiencies across key units contributed to a notable improvement in EBIT. FY25 was marked by strategic consolidation and investments focused on capacity enhancement, improved utilization, cost control, and regulatory expansion. Our strong backward integration model continues to drive cost control, supply reliability, and operating leverage. We remain committed to strengthening our portfolio, driving operational excellence, and expanding our market reach to create sustained value.” Result PDF